Drug intelligence / Profile preview

Hemay5087

Development stage: Phase 1
Lead developer: Tianjin Hemay Biotech
Modality: Small Molecules

Overview

Hemay5087 is a preclinical-stage small molecule therapeutic being developed by Tianjin Hemay Bio-Tech for the treatment of solid tumors. As an early-stage oncology asset, its specific molecular target and mechanism of action have not yet been publicly disclosed by the developer. The drug is part of Tianjin Hemay's broader pipeline of small molecule inhibitors aimed at addressing unmet needs in oncology and inflammatory diseases.

Beyond the preview

Go deeper on Hemay5087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemay5087.

Explore the full profile